Patents by Inventor Oliver Seifert

Oliver Seifert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11958519
    Abstract: A method for operating a railway system. Cryptographic data which includes at least one key and/or at least one digital certificate is stored in a storage device of a vehicle of the railway system. The vehicle transmits the cryptographic data to at least one track-side device of the railway system when the vehicle is in communication range of the least one track-side device as part of the train travel. There is also described a corresponding rail vehicle of a railway system.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 16, 2024
    Assignee: Siemens Mobility GmbH
    Inventors: Oliver Schulz, Matthias Seifert
  • Patent number: 11935363
    Abstract: A described gaming system implements an arrangement wherein, as part of a first base game instance, a gaming device is caused to include, at a first symbol position of a symbol array to be implemented by a gaming device, a first Wild symbol at a first symbol position on a reel of a plurality of reels; and, as part of a second base game instance following the first game instance, a modification of the reel of the plurality of reels is performed to move the first Wild symbol into a second symbol position different than the first symbol position.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: March 19, 2024
    Assignee: Aristocrat Technologies Australia Pty Limited
    Inventors: Natalie Bryant, Philip Seifert, Nicole Hedley, Ronald Dy, Doanh Dang, Oliver Crispino
  • Publication number: 20240059779
    Abstract: The present invention relates to a modular multivalent antigen-binding protein complex, use of the antigen-binding protein complex in medicine and use of the antigen-binding protein complex in the prophylaxis, treatment or diagnosis of a disorder or disease.
    Type: Application
    Filed: August 21, 2023
    Publication date: February 22, 2024
    Inventors: Oliver SEIFERT, Roland KONTERMANN, Fabian RICHTER
  • Patent number: 11851489
    Abstract: The present invention provides a protein complex comprising heterodimerizing regions HRI and HRII, each comprised of antiparallel ?-strands and intervening regions wherein HRI and HRII are each interspersed fusion proteins of two human constant regions of an immunoglobulin or immunoglobulin-like proteins. The present invention also provides nucleic acid molecules comprising a sequence encoding said protein complexes and vectors comprising the nucleic acid. The present invention also provides the protein complex, the nucleic acid and the vector for use as a medicament. The present invention further provides a method of determining the amino acid sequence of HRI and/or of the amino acid sequence of HRII. The present invention also provides a method of producing amino acid chains of HRI and/or amino acid chains of HRII. The present invention further provides the protein complex for use in the N prophylaxis, treatment or diagnosis of a disorder or a disease.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: December 26, 2023
    Assignee: UNIVERSITÄT STUTTGART
    Inventors: Fabian Richter, Oliver Seifert, Roland Kontermann
  • Patent number: 11780926
    Abstract: The present invention relates to a modular multivalent antigen-binding protein complex, use of the antigen-binding protein complex in medicine and use of the antigen-binding protein complex in the prophylaxis, treatment or diagnosis of a disorder or disease.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: October 10, 2023
    Assignee: UNIVERSITÄT STUTTGART
    Inventors: Oliver Seifert, Roland Kontermann, Fabian Richter
  • Publication number: 20220396635
    Abstract: The present invention relates to a trivalent binding molecule comprising a first polypeptide comprising two binding domains and a second polypeptide comprising a third binding domain. The present invention further relates to the trivalent binding molecule for use in medicine and in particular in the prophylaxis, treatment or diagnosis of a disorder or disease.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 15, 2022
    Inventors: Roland KONTERMANN, Oliver SEIFERT, Nadine ASCHMONEIT
  • Publication number: 20220372147
    Abstract: The present invention relates to binding molecules comprising two polypeptide chains, wherein the peptide chains comprise modified EHD2 domains allowing heterodimerization only, thereby preventing homodimers, nucleic acids encoding such binding molecules and uses of such binding molecules or nucleic acids encoding such binding molecules in therapy.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 24, 2022
    Inventors: Roland KONTERMANN, Oliver SEIFERT
  • Patent number: 11008402
    Abstract: The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 18, 2021
    Inventors: Roland Kontermann, Lisa Schmitt, Meike Hutt, Oliver Seifert, Monilola Olayioye, Michael Hust, Stefan Dübel, Jonas Zantow
  • Publication number: 20210139606
    Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.
    Type: Application
    Filed: November 9, 2020
    Publication date: May 13, 2021
    Applicant: UNIVERSITAT STUTTGART
    Inventors: Roland KONTERMANN, Oliver SEIFERT, Aline PLAPPERT
  • Publication number: 20210002376
    Abstract: The present invention relates to a modular multivalent antigen-binding protein complex, use of the antigen-binding protein complex in medicine and use of the antigen-binding protein complex in the prophylaxis, treatment or diagnosis of a disorder or disease.
    Type: Application
    Filed: March 22, 2018
    Publication date: January 7, 2021
    Inventors: Oliver SEIFERT, Roland KONTERMANN, Fabian RICHTER
  • Patent number: 10875928
    Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: December 29, 2020
    Assignee: UNIVERSITÄT STUTTGART
    Inventors: Roland Kontermann, Oliver Seifert, Aline Plappert
  • Publication number: 20200172619
    Abstract: The present invention provides a protein complex comprising heterodimerizing regions HRI and HRII, each comprised of antiparallel ?-strands and intervening regions wherein HRI and HRII are each interspersed fusion proteins of two human constant regions of an immunoglobulin or immunoglobulin-like proteins. The present invention also provides nucleic acid molecules comprising a sequence encoding said protein complexes and vectors comprising the nucleic acid. The present invention also provides the protein complex, the nucleic acid and the vector for use as a medicament. The present invention further provides a method of determining the amino acid sequence of HRI and/or of the amino acid sequence of HRII. The present invention also provides a method of producing amino acid chains of HRI and/or amino acid chains of HRII. The present invention further provides the protein complex for use in the N prophylaxis, treatment or diagnosis of a disorder or a disease.
    Type: Application
    Filed: June 1, 2018
    Publication date: June 4, 2020
    Inventors: Fabian RICHTER, Oliver SEIFERT, Roland KONTERMANN
  • Patent number: 10428149
    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 1, 2019
    Assignee: UNIVERSITAT STUTTGART
    Inventors: Ugur Sahin, Roland Kontermann, Klaus Pfizenmaier, Martin Siegemund, Meike Hutt, Oliver Seifert
  • Publication number: 20190194350
    Abstract: The present invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The present invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The present invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament.
    Type: Application
    Filed: September 15, 2017
    Publication date: June 27, 2019
    Inventors: Roland KONTERMANN, Lisa SCHMITT, Meiko HUTT, Oliver SEIFERT, Monilola OLAYIOYE, Michael HUST, Stefan DÜBEL, Jonas ZANTOW
  • Publication number: 20180094059
    Abstract: The present invention relates to a polypeptide comprising a component A with at least three tumor necrosis factor (TNF) homology domains of TNF-ligand family members (THD) in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof, and a component B comprising a dimerization domain. Further, the present invention relates to a polypeptide comprising at least three THDs in which C-terminal and N-terminal reference points are defined by consensus sequences and which are connected through short stretches of additional C-terminal and/or N-terminal amino acids of the THD or variants thereof. Further, the invention relates to a nucleic acid comprising said polypeptides, a vector comprising said nucleic acid and a pharmaceutical composition comprising said polypeptides, or said nucleic acids or said vector.
    Type: Application
    Filed: March 18, 2016
    Publication date: April 5, 2018
    Inventors: Ugur SAHIN, Roland KONTERMANN, Klaus PFIZENMAIER, Martin SIEGEMUND, Meike HUTT, Oliver SEIFERT
  • Publication number: 20170327594
    Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.
    Type: Application
    Filed: July 10, 2017
    Publication date: November 16, 2017
    Applicant: UNIVERSITÄT STUTTGART
    Inventors: Roland KONTERMANN, Oliver SEIFERT, Aline PLAPPERT
  • Publication number: 20150056159
    Abstract: The present invention provides a polypeptides comprising a heavy chain domain 2 (HD2) from IgM or IgE and at least one pharmaceutically active moiety, complexes thereof and their use for therapy and prophylaxis.
    Type: Application
    Filed: April 16, 2013
    Publication date: February 26, 2015
    Applicant: UNIVERSIT T STUTTGART
    Inventors: Roland Kontermann, Oliver Seifert, Aline Plappert
  • Publication number: 20080036621
    Abstract: A method for transmitting measured values between two measurement transmitters, which transmit, via two communication connections, digital signals according to the master/slave principle and analog signals to a control system, which serves as the master, comprises the steps of: transmitting the digital signals between the two measurement transmitters via an additional communication connection; and the incoming digital signals in the receiver measurement transmitter are examined for at least one characteristic value of the transmitting measurement transmitter, in order to find measured values needed for evaluation in the receiver measurement transmitter.
    Type: Application
    Filed: November 4, 2004
    Publication date: February 14, 2008
    Inventors: Ole Koudal, Oliver Popp, Oliver Seifert, Ralf Uehlin, Walter Borst